Equities

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.82
  • Today's Change-0.37 / -4.52%
  • Shares traded1.70m
  • 1 Year change+57.03%
  • Beta1.8164
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

  • Revenue in USD (TTM)412.58m
  • Net income in USD-123.82m
  • Incorporated1991
  • Employees536.00
  • Location
    BioCryst Pharmaceuticals Inc4505 Emperor Blvd Ste 200DURHAM 27703-8457United StatesUSA
  • Phone+1 (919) 859-1302
  • Fax+1 (919) 859-1314
  • Websitehttps://www.biocryst.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rocket Pharmaceuticals Inc0.00-258.08m1.53bn268.00--4.66-----2.75-2.750.003.620.00----0.00-52.01-35.26-56.17-37.49------------0.0605-------10.70--62.52--
Gyre Therapeutics Inc165.85m-79.66m1.57bn593.00--23.81--9.46-0.8638-0.86381.430.70562.49--17.81279,674.50-103.20-73.59-167.87-99.9496.15---41.48-205.623.07--0.00--14,188.41616.69-1,027.55--86.95--
Praxis Precision Medicines Inc1.61m-151.02m1.58bn82.00--3.94--985.07-10.29-10.290.105821.520.0061----19,573.17-57.75-74.04-63.81-85.12-----9,409.22-24,589.25----0.00------42.40---4.52--
Day One Biopharmaceuticals Inc101.95m-84.29m1.60bn174.00--2.88--15.69-1.02-1.021.145.510.2009----657,761.30-16.61---17.73--97.75---82.68--14.55--0.00-------32.87------
Arcus Biosciences Inc263.00m-270.00m1.62bn577.00--2.87--6.18-3.15-3.153.066.170.2153--6.83455,805.90-22.10-15.85-26.63-18.25-----102.66-103.46----0.0768--4.4669.54-14.98--45.01--
Travere Therapeutics Inc203.45m-348.96m1.63bn380.00------8.02-4.52-4.562.63-0.39090.30430.719210.24535,386.80-52.19-36.95-69.25-44.7795.2195.92-171.52-165.791.68--1.09--32.69-2.43-13.54--16.49--
Xencor Inc85.16m-198.24m1.63bn280.00--2.25--19.15-3.20-3.201.3710.350.0967--2.61304,157.20-22.89-3.70-24.90-4.12-----236.81-15.92----0.0243--2.2832.90-128.50--18.36--
Kiniksa Pharmaceuticals Ltd384.10m-9.07m1.66bn297.00--3.80--4.33-0.1584-0.15845.286.060.73981.9427.511,293,259.00-1.75-16.49-2.04-18.7286.31---2.36-53.642.95--0.00--22.74---92.32---52.35--
Bicycle Therapeutics PLC (ADR)36.90m-166.28m1.68bn284.00--2.02--45.51-3.28-3.280.716312.040.0451--0.9806129,922.50-20.33-29.45-22.03-32.98-----450.64-571.36----0.0002--86.5230.47-60.28--19.82--
ARS Pharmaceuticals Inc500.00k-44.84m1.70bn23.00--7.88--3,391.02-0.466-0.4660.00522.220.0021----20,833.33-18.66-20.37-19.33-21.32-----8,968.40-17,491.75----0.00---97.72---56.75---17.18--
BioCryst Pharmaceuticals Inc412.58m-123.82m1.70bn536.00------4.11-0.6073-0.60732.01-2.260.81360.42976.54769,736.90-24.42-47.95-32.17-64.8998.0697.06-30.01-114.942.73-0.4882.29--22.3774.218.33--42.73--
Celldex Therapeutics, Inc.9.98m-154.08m1.74bn160.00--2.21--174.31-2.57-2.570.16411.850.0181--18.0762,350.00-27.93-29.65-29.53-31.42-----1,544.48-1,747.94----0.00--192.02-6.32-25.91--17.46--
Intellia Therapeutics Inc43.09m-522.28m1.78bn526.00--1.85--41.26-5.45-5.450.45099.460.0357--5.6281,912.55-43.22-31.34-47.07-34.53-----1,212.19-654.71----0.00---30.403.57-1.48--17.08--
Dynavax Technologies Corp260.81m20.48m1.79bn408.00111.902.6371.506.860.12210.12211.835.190.25630.804.36639,242.602.014.162.145.7182.8564.837.859.1912.34--0.2470.00-67.8695.19-102.18---23.03--
Data as of Nov 12 2024. Currency figures normalised to BioCryst Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

44.16%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Oct 202420.73m10.02%
BlackRock Fund Advisorsas of 30 Jun 202416.52m7.98%
Avoro Capital Advisor LLCas of 30 Jun 202412.57m6.08%
SSgA Funds Management, Inc.as of 30 Sep 20248.85m4.28%
Kynam Capital Management LPas of 30 Jun 20248.83m4.27%
Alkeon Capital Management LLCas of 30 Jun 20247.10m3.43%
Geode Capital Management LLCas of 30 Jun 20244.71m2.28%
Caligan Partners LPas of 30 Jun 20244.60m2.22%
RP Management LLC (Investment Management)as of 30 Jun 20243.85m1.86%
Rock Springs Capital Management LPas of 30 Jun 20243.62m1.75%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.